Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2-early breast cancer: a discrete choice survey study

被引：0

作者：

Mayer, Erica L. ^{[1
]}

Smith, Mary Lou ^{[2
]}

Guerin, Annie ^{[3
]}

Latremouille-Viau, Dominick ^{[3
]}

Hazra, Nisha C. ^{[4
]}

Meng, Yan ^{[4
]}

Qu, Wendi ^{[3
]}

Bellefleur, Remi ^{[3
]}

Ganapathy, Vaidyanathan ^{[5
]}

Santarsiero, Liz ^{[5
]}

Morlock, Robert ^{[6
]}

Lustberg, Maryam B. ^{[7
]}

机构：

[1] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA

[2] Res Advocacy Network, Plano, TX USA

[3] Grp Anal Ltee, Montreal, PQ, Canada

[4] Anal Grp Inc, London, England

[5] Novartis Pharmaceut, E Hanover, NJ USA

[6] YourCareChoice, Ann Arbor, MI USA

[7] Smilow Canc Hosp Yale New Haven, New Haven, CT USA

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2025年

关键词：

Patient preference; CDK4/6; inhibitor; Early breast cancer; Discrete choice experiment; CONJOINT-ANALYSIS APPLICATIONS; ADJUVANT ENDOCRINE THERAPY; INTERIM ANALYSIS; OPEN-LABEL; HEALTH; PALBOCICLIB; ONCOLOGIST; REGIMENS; STAGE;

D O I：

10.1007/s10549-025-07627-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PurposeAdding CDK4/6 inhibitors (CDK4/6is) to endocrine therapy (ET) for HR+/HER2- early breast cancer (EBC) demonstrated statistically significant invasive disease-free survival (iDFS) benefits in monarchE (node positive, high risk, stage II/III) and NATALEE (select N0 and all macroscopic N1, stage II/III). This study evaluated patient preferences for EBC treatment attributes and how these may translate for CDK4/6i selection.MethodsA web-based discrete choice experiment survey was conducted among US-based adult women with self-reported stage II/III HR+/HER2- EBC. Eight attributes were included, informed by 14 qualitative interviews (to identify most relevant attributes), expert clinical input, and differentiating features between CDK4/6is: efficacy (5-year iDFS), adverse events (venous thromboembolic event [VTE], diarrhea, fatigue), number of blood tests, number of electrocardiograms (EKGs), treatment duration, and schedule. Participants selected scenarios that best reflected their preferences from 10 choice cards, each displaying a pair of hypothetical treatment profiles. A conditional logit regression model was used to estimate preference weights and relative importance (RI) of attributes.ResultsA total of 409 women participated. Patient preferences, from high to low RI, were higher efficacy, lower diarrhea risk, lower fatigue risk, shorter treatment duration, and lower VTE risk. Number of blood tests, number of EKGs, and treatment schedule were less important. Utility scores were higher for reconstructed treatment profiles that resembled ribociclib.ConclusionThis study demonstrated that patients prefer adjuvant treatment with higher efficacy and lower risk of adverse events. These data will aid shared decision-making when discussing the addition of CDK4/6is to adjuvant ET for eligible patients with HR+/HER2- EBC.

引用

页码：121 / 130

页数：10